Research programme: antianaemic antibody therapeutics - Alder

Drug Profile

Research programme: antianaemic antibody therapeutics - Alder

Alternative Names: ALD 401 - Alder

Latest Information Update: 13 Dec 2010

Price : $50

At a glance

  • Originator Alder Biopharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 04 Dec 2008 Preclinical trials in Anaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top